← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oasis Pharmaceuticals
Lexington, MA
$12,297,756
Total funding
9
Grants
Funding over time
peak $2.2M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,297,756 · 9
By mechanism
R42$7,543,296 · 4
R44$3,165,348 · 1
R41$1,589,112 · 4
Investigators at Oasis Pharmaceuticals
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of PAR2 Pepducins as a Novel NASH Treatment$1,060,598
R44 · FY2018 · DK
Development of PAR2 Pepducins as a Novel NASH Treatment$1,056,106
R44 · FY2019 · DK
Development of PAR2 Pepducins as a Novel NASH Treatment$1,048,644
R44 · FY2017 · DK
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy$999,799
R42 · FY2023 · HL
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy$999,799
R42 · FY2024 · HL
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis$871,604
R42 · FY2014 · DK
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis$871,014
R42 · FY2015 · DK
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis$750,502
R42 · FY2019 · HL
Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis$750,000
R42 · FY2017 · AR
Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis$750,000
R42 · FY2016 · AR
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis$740,572
R42 · FY2020 · HL
Development of PAR2 Pepducins for the Treatment of COPD$468,369
R41 · FY2025 · HL
Development of liver homing PAR2 pepducins for the treatment of Hepatocellular Carcinoma$392,485
R41 · FY2022 · CA
Development of PAR4 Pepducins as a Novel Antithrombotic Treatment$366,484
R41 · FY2017 · HL
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy$361,774
R41 · FY2021 · HL
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis$304,237
R42 · FY2013 · DK
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis$225,769
R42 · FY2018 · HL
Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis$225,000
R42 · FY2015 · AR
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy$50,000
R42 · FY2025 · HL
Supplement to grant 5R42DK101240 Oasis Pharmaceuticals to attend BIO conference$5,000
R42 · FY2015 · DK